Ipsen – Half year statement – 2023 06 30
Half-year statement of IPSEN liquidity agreement with NATIXIS ODDO BHF
Paris (France), July 10, 2023 – Under the liquidity agreement entrusted by IPSEN SA to NATIXIS ODDO BHF, as of June 30, 2023, the following resources were included to the dedicated liquidity account:
- 17,348 shares
- €3,350,842.85
It is reminded that as of the date of the signature of the agreement, the following assets were allocated to the liquidity account:
- 12,751 shares
- €3,137,934.80
Between January 1st, 2023 and June 30, 2023 have been executed:
- 3,153 purchase transactions
- 2,820 sell transactions
Under the same period, the volumes traded represented:
- 360,894 shares and €38,313,096.35 to the purchase
- 367,615 shares and €39,180,843.15 to the sell
Attachment
Ipsen – Half year statement – 2023 06 30
Half-year statement of IPSEN liquidity agreement with NATIXIS ODDO BHF
Paris (France), July 10, 2023 – Under the liquidity agreement entrusted by IPSEN SA to NATIXIS ODDO BHF, as of June 30, 2023, the following resources were included to the dedicated liquidity account:
- 17,348 shares
- €3,350,842.85
It is reminded that as of the date of the signature of the agreement, the following assets were allocated to the liquidity account:
- 12,751 shares
- €3,137,934.80
Between January 1st, 2023 and June 30, 2023 have been executed:
- 3,153 purchase transactions
- 2,820 sell transactions
Under the same period, the volumes traded represented:
- 360,894 shares and €38,313,096.35 to the purchase
- 367,615 shares and €39,180,843.15 to the sell
Attachment
Related Press Releases

Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA

Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC

US FDA approves Ipsen’s Sohonos™ (palovarotene) capsules, the first and only treatment for people with fibrodysplasia ossificans progressiva

IPSEN – Buy-back programme – Art 5 of MAR – Week 27 – 2023

Ipsen – Monthly information relative to the total number of voting rights and shares composing the share capital

IPSEN – Buy-back programme – Art 5 of MAR – Week 26 – 2023

Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease

Ipsen announces positive outcome of FDA Advisory Committee on investigational palovarotene for fibrodysplasia ossificans progressiva
